Follow FrankTwisk on Twitter  





Lezing Mikovits


(NYAS, 2011)






Judy Mikovits verzorgt op 29 maart 2011 in New York een lezing,

waarin zij de aktuele stand van zaken rond XMRV/MLV uit de doeken zal doen.


De lezing vindt plaats onder auspiciŽn van de New York Academy of Sciences.

Vreemd dat zo'n prestigieuze organisatie aandacht besteed aan een "irrelevant virus"...






Pathogens in the Blood Supply


Tuesday, March 29, 2011, 1:00 PM - 5:00 PM

The New York Academy of Sciences


Presented by the Emerging Infectious Diseases & Microbiology Discussion Group



According to America's Blood Centers,

approximately 14 million units of blood are transfused in the United States every year.


Current screening protocols routinely test for several pathogens,

including the Hepatitis B virus, Hepatitis C virus, Human Immunodeficiency viruses,

Types 1 and 2, Human T-Lymphotropic virus Types 1 and 2 and syphilis.


Recent headlines indicate that the blood supply may contain other organisms,

such as Xenotropic Murine Leukemia Virus Related Virus (XMRV),

that are not currently being identified in these routine screens.


This symposium will diagnose the current problems, reveal recent advances in the testing

and screening of the blood supply, and will explore future directions.






Disease Associations of XMRV and MLV-Related Viruses


Judy A. Mikovits, PhD,

Whittemore Peterson Institute for Neuro-Immune Disease



A new human retrovirus

first associated with QQ variant RNaseL, a gene in the hereditary prostate cancer gene locus,

in prostate cancer in 2006.


Detection of integration sites in unmanipulated prostate tissue;

demonstration of neutralizing antibody and in situ hybridization for XMRV,

supports XMRV as a human retroviral infection associated with prostate cancer.


Although in the absence of direct sequencing

it cannot be rule out the reactivity can be to related MLV viruses.


In 2009 using

a classical virology approach of viral isolation and transmission,

electron micropscopy, serology and PCR,

Lombardi et al demonstrated

the first isolation of XMRV from blood

from patients with chronic fatigue syndrome (CFS)

predominately from the west coast of the United States.


In 2010,

Lo et al. extended these studies

by detecting nucleic acids of MLV-related variants

in the peripheral blood mononuclear cells of CFS

from the northeastern United States

suggesting additional strains capable of infecting humans exist.


In a study of 300 CFS patients,

13 developed lymphoproliferative disorders.


Of those tested,

11/11 were positive for XMRV and 9/9 positive for clonalTCR gamma rearrangements.


Spontaneous development of four immortalized B cells lines occurred

during culture of cells from CFS patients.


Three developed from B cells

isolated from the peripheral blood

(two of whom had B cell lymphoma) and

one from a bone marrow biopsy.


The B cell lines have

a mature CD20+, CD23+ phenotype and

produce infectious XMRV.


Virus production occurred

despite extensive hypermutation of the proviruses in these cells




XMRV infection may accelerate the development of B cell malignancies

by either indirect chronic stimulation of the immune system

and/or by direct infection of the B-cell lineage.


Since viral load in peripheral blood is low,

these data suggest that

B cells in tissues such as spleen and lymph nodes

could be an in vivo reservoir for XMRV.


We have also identified

an inflammatory cytokine and chemokine signature

that distinguishes XMRV infected CFS patients from healthy controls

with 94% sensitivity and specificity.


Monitoring immune dysfunction

affords the opportunity to begin to understand

the pathogenesis of XMRVs.


In addition to these data,

recent advances in developing tests for detection and characterization of XMRVĖvariants

will be also be discussed




Met dank aan Erik, onbezoldigd korrespondent/ME-de-patiŽnt.